Inactive

Roche Venture Fund

Investor type

CVC

Founded

1896

AUM

$850 M

Location

Basel, Basel-Stadt, Switzerland

Investment Ticket

$10-50 m

Investment Stage

Series A Seed Series B Late Stage (Series C+)

Region of investment

North America Europe Asia

ESG Focus

Impact investor
Investor profile last updated: 30 August, 2026

Profile

Roche Venture Fund is a corporate venture capital fund headquartered in Basel, Switzerland. It was established as the investment arm of Roche, a global healthcare company with a rich history in biotechnology and pharmaceuticals. The fund operates with a dedicated team, focused on identifying and investing in pioneering healthcare innovations. As part of a well-established pharmaceutical giant, Roche Venture Fund benefits from deep industry knowledge and a wide network of strategic partners.

The investment strategy of Roche Venture Fund primarily targets the life sciences sector, including biotechnology, pharmaceuticals, diagnostics, and personalized healthcare. They typically invest in Series A and beyond, with a global mandate that spans North America, Europe, and Asia. The fund capitalizes on the synergies with Roche's core business areas, aiming to nurture innovative science into commercial reality.

Roche Venture Fund has a diverse portfolio that includes exciting companies such as C4 Therapeutics - a biotech firm focused on degrader therapeutics, Mission Therapeutics - a company developing DUB inhibitors, and FORMA Therapeutics - known for its focus on cancer and hematologic diseases. Their investments often align with Roche's strategic interests, facilitating both financial return and strategic collaboration potential.

Industry

HealthTech Biotechnology Healthcare Services Medical Devices Pharmaceuticals Software MedTech Life Sciences

Roche Venture Fund Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
Roche Venture Fund
Corporate VC (CVC)
Biotechnology
Healthcare Services
Medical Devices
Pharmaceuticals
MedTech
Life Sciences
Seed
Series A
Series B
North America
$5-10 m
$516 M
December 2002

Contacts

Name
Title
Email
avatar
Monte Curnutt Vice President Corporate Development at Roche Diagnostics USA
Vice President Corporate Development at Roche Diagnostics USA
m•••@•••
avatar
Anna Williamson Executive Director & UK Partnering Lead, Pharma Partnering at Roche/Genentech
Executive Director & UK Partnering Lead, Pharma Partnering at Roche/Genentech
a•••@•••
Upgrade to see contacts
avatar
WJ3L0xlwHp5bueQy WJ3L0xlwHp5bueQy
WJ3L0xlwHp5bueQy
avatar
WJ3L0xlwHp5bueQy WJ3L0xlwHp5bueQy
WJ3L0xlwHp5bueQy
avatar
WJ3L0xlwHp5bueQy WJ3L0xlwHp5bueQy
WJ3L0xlwHp5bueQy
Investment-team contacts for Roche Venture Fund — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Roche Venture Fund

Roche Venture Fund operates as a corporate VC (CVC). It backs companies at Series A, Seed, Series B and Late Stage (Series C+), writing tickets of $10-50 m.
Roche Venture Fund is located in Basel, Basel-Stadt, Switzerland.
Roche Venture Fund was founded in 1896.
Roche Venture Fund invests in companies and startups in HealthTech, Biotechnology, Healthcare Services, Medical Devices, Pharmaceuticals, Software, MedTech, Life Sciences.
Roche Venture Fund invests in companies and startups in North America, Europe, Asia.
Roche Venture Fund invests in companies and startups at Series A, Seed, Series B, Late Stage (Series C+).
Roche Venture Fund usually invests $10-50 m on average.
Roche Venture Fund has around $850m assets under management.
Roche Venture Fund last fund was created/launched in 2002-12-17
Yes, Roche Venture Fund is impact investor.
Roche Venture Fund can be reached through its website roche.com/careers, its LinkedIn page and its X account. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Roche Venture Fund — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Roche Venture Fund directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 30 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.